Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo

Yun Ning, A. G P Schuller, Cheryl A Conover, John E. Pintar

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

IGFs are required for normal prenatal and postnatal growth. Although actions of IGFs can be modulated by a family of IGF-binding proteins (IGFBPs) in vitro, these studies have identified a complicated pattern of stimulatory and inhibitory IGFBP effects, so that understanding relevant aspects of IGFBP action in vivo has been limited. Here we have produced a null mutation of one specific IGFBP, IGFBP-4, which is coexpressed with IGF-II early in development. Surprisingly, mutation of IGFBP-4, believed from in vitro studies to be exclusively inhibitory, leads to a prenatal growth deficit that is apparent from the time that the IGF-II growth deficit first arises, which strongly suggests that IGFBP-4 is required for optimal IGF-II-promoted growth during fetal development. Mice encoding a mutant IGFBP-4 protease (pregnancy-associated plasma protein-A), which facilitates IGF-II release from an inactive IGF-II/IGFBP-4 complex in vitro, are even smaller than IGFBP-4 mutant mice. However, the more modest IGFBP-4 growth deficit is completely restored in double IGFBP-4/pregnancy-associated plasma protein-A-deficient mice. Taken together these results indicate not only that IGFBP-4 functions as a local reservoir to optimize IGF-II actions needed for normal embryogenesis, but also establish that IGFBP-4 proteolysis is required to activate most, if not all, IGF-II mediated growth-promoting activity.

Original languageEnglish (US)
Pages (from-to)1213-1225
Number of pages13
JournalMolecular Endocrinology
Volume22
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Insulin-Like Growth Factor Binding Protein 4
Somatomedins
Insulin-Like Growth Factor II
Insulin-Like Growth Factor Binding Proteins
Pregnancy-Associated Plasma Protein-A
Growth
Mutation
Mutant Proteins
Fetal Development
Protein Binding
Proteolysis
Embryonic Development
Peptide Hydrolases

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo. / Ning, Yun; Schuller, A. G P; Conover, Cheryl A; Pintar, John E.

In: Molecular Endocrinology, Vol. 22, No. 5, 05.2008, p. 1213-1225.

Research output: Contribution to journalArticle

@article{f5fe9302f1e04c0eb8fb26f7bfc2041d,
title = "Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo",
abstract = "IGFs are required for normal prenatal and postnatal growth. Although actions of IGFs can be modulated by a family of IGF-binding proteins (IGFBPs) in vitro, these studies have identified a complicated pattern of stimulatory and inhibitory IGFBP effects, so that understanding relevant aspects of IGFBP action in vivo has been limited. Here we have produced a null mutation of one specific IGFBP, IGFBP-4, which is coexpressed with IGF-II early in development. Surprisingly, mutation of IGFBP-4, believed from in vitro studies to be exclusively inhibitory, leads to a prenatal growth deficit that is apparent from the time that the IGF-II growth deficit first arises, which strongly suggests that IGFBP-4 is required for optimal IGF-II-promoted growth during fetal development. Mice encoding a mutant IGFBP-4 protease (pregnancy-associated plasma protein-A), which facilitates IGF-II release from an inactive IGF-II/IGFBP-4 complex in vitro, are even smaller than IGFBP-4 mutant mice. However, the more modest IGFBP-4 growth deficit is completely restored in double IGFBP-4/pregnancy-associated plasma protein-A-deficient mice. Taken together these results indicate not only that IGFBP-4 functions as a local reservoir to optimize IGF-II actions needed for normal embryogenesis, but also establish that IGFBP-4 proteolysis is required to activate most, if not all, IGF-II mediated growth-promoting activity.",
author = "Yun Ning and Schuller, {A. G P} and Conover, {Cheryl A} and Pintar, {John E.}",
year = "2008",
month = "5",
doi = "10.1210/me.2007-0536",
language = "English (US)",
volume = "22",
pages = "1213--1225",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo

AU - Ning, Yun

AU - Schuller, A. G P

AU - Conover, Cheryl A

AU - Pintar, John E.

PY - 2008/5

Y1 - 2008/5

N2 - IGFs are required for normal prenatal and postnatal growth. Although actions of IGFs can be modulated by a family of IGF-binding proteins (IGFBPs) in vitro, these studies have identified a complicated pattern of stimulatory and inhibitory IGFBP effects, so that understanding relevant aspects of IGFBP action in vivo has been limited. Here we have produced a null mutation of one specific IGFBP, IGFBP-4, which is coexpressed with IGF-II early in development. Surprisingly, mutation of IGFBP-4, believed from in vitro studies to be exclusively inhibitory, leads to a prenatal growth deficit that is apparent from the time that the IGF-II growth deficit first arises, which strongly suggests that IGFBP-4 is required for optimal IGF-II-promoted growth during fetal development. Mice encoding a mutant IGFBP-4 protease (pregnancy-associated plasma protein-A), which facilitates IGF-II release from an inactive IGF-II/IGFBP-4 complex in vitro, are even smaller than IGFBP-4 mutant mice. However, the more modest IGFBP-4 growth deficit is completely restored in double IGFBP-4/pregnancy-associated plasma protein-A-deficient mice. Taken together these results indicate not only that IGFBP-4 functions as a local reservoir to optimize IGF-II actions needed for normal embryogenesis, but also establish that IGFBP-4 proteolysis is required to activate most, if not all, IGF-II mediated growth-promoting activity.

AB - IGFs are required for normal prenatal and postnatal growth. Although actions of IGFs can be modulated by a family of IGF-binding proteins (IGFBPs) in vitro, these studies have identified a complicated pattern of stimulatory and inhibitory IGFBP effects, so that understanding relevant aspects of IGFBP action in vivo has been limited. Here we have produced a null mutation of one specific IGFBP, IGFBP-4, which is coexpressed with IGF-II early in development. Surprisingly, mutation of IGFBP-4, believed from in vitro studies to be exclusively inhibitory, leads to a prenatal growth deficit that is apparent from the time that the IGF-II growth deficit first arises, which strongly suggests that IGFBP-4 is required for optimal IGF-II-promoted growth during fetal development. Mice encoding a mutant IGFBP-4 protease (pregnancy-associated plasma protein-A), which facilitates IGF-II release from an inactive IGF-II/IGFBP-4 complex in vitro, are even smaller than IGFBP-4 mutant mice. However, the more modest IGFBP-4 growth deficit is completely restored in double IGFBP-4/pregnancy-associated plasma protein-A-deficient mice. Taken together these results indicate not only that IGFBP-4 functions as a local reservoir to optimize IGF-II actions needed for normal embryogenesis, but also establish that IGFBP-4 proteolysis is required to activate most, if not all, IGF-II mediated growth-promoting activity.

UR - http://www.scopus.com/inward/record.url?scp=43049104176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049104176&partnerID=8YFLogxK

U2 - 10.1210/me.2007-0536

DO - 10.1210/me.2007-0536

M3 - Article

VL - 22

SP - 1213

EP - 1225

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 5

ER -